Nuveen
IMDX

Nuveen’s Insight Molecular Diagnostics IMDX Stock Holding History

Nuveen’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,375
Closed -$1.45M – 3418
2022
Q1 		$1.45M Sell
51,375
-13,451
-21% -$430K ﹤0.01% 2661
2021
Q4 		$2.72M Sell
64,826
-5,608
-8% -$323K ﹤0.01% 2409
2021
Q3 		$5.59M Sell
70,434
-2,674
-4% -$246K ﹤0.01% 2140
2021
Q2 		$8.39M Buy
73,108
+24,166
+49% +$2.36M ﹤0.01% 1978
2021
Q1 		$5.08M Buy
48,942
+36,795
+303% +$3.49M ﹤0.01% 2162
2020
Q4 		$580K Buy
12,147
+1,080
+10% +$39.6K ﹤0.01% 3004
2020
Q3 		$308K Sell
11,067
-2,959
-21% -$84.8K ﹤0.01% 3083
2020
Q2 		$536K Buy
14,026
+9,699
+224% +$501K ﹤0.01% 2870
2020
Q1 		$212K Buy
4,327
+1,383
+47% +$67.8K ﹤0.01% 2985
2019
Q4 		$132K Sell
2,944
-401
-12% -$14.5K ﹤0.01% 3109
2019
Q3 		$141K Sell
3,345
-1,590
-32% -$62.5K ﹤0.01% 3149
2019
Q2 		$246K Buy
+4,935
New +$410K ﹤0.01% 3153

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Nuveen's IMDX Position: Q2 2022 in Review

Nuveen sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 51,375 shares — an estimated $1.45M sold.

Nuveen first reported a position in IMDX in Q2 2019 and held it in 12 quarters. The position peaked at $8.39M in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Nuveen reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 51,375 Insight Molecular Diagnostics shares in Q2 2022, an estimated $1.45M.
  • Nuveen first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 12 quarters.
  • Nuveen's Insight Molecular Diagnostics position peaked at $8.39M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.